Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cardiovascular devices

This article was originally published in Start Up

Executive Summary

Two areas of heart disease in want of therapeutic solutions are attracting device innovation: atrial fibrillation and congestive heart failure. Successful developers will be rewarded by large markets with little in terms of current competition.

You may also be interested in...



AHA Wrap-Up: Studies Emphasize Improved Outcomes, Cost Effectiveness

Cardiovascular investigators are now asking new questions, including how can treatment be targeted to those most likely to benefit, and when does aggressive treatment become too much? At the 2006 American Heart Association (AHA) meeting, these questions were at the top of everyone's list, and several highly anticipated studies attempted to provide some answers.

Deal Statistics Quarterly, Q2 2005

In this issue, we present another installment of our quarterly review of dealmaking-for April-June 2005. Our data comes from Windhover's Strategic Intelligence Systems, which covers deal activity within the pharmaceutical/biotechnology, medical device, and in vitro diagnostics industries.

Acorn Cardiovascular Inc.

Acorn Cardiovascular Inc. has developed a device for the treatment of congestive heart failure. It operates under the same theory as cardiac wrapping, but is less invasive and less costly. Acorn's "jacket" made of synthetic fibers surrounds the heart and constrains it, preventing the cascade of progressive enlargement and weakening that accompanies CHF. According to Acorn's president and CEO Donald G. Rohrbaugh, the jacket's fibers are knitted into a unique configuration designed to conform closely to the heart's exterior. Special compliance properties provide uniform contact so that there are no particular stress points. During implantation, the device is tailored to provide a 5% reduction in the diameter of the heart. That reduction immediately helps to absorb some of the stress in the heart's wall and allows the myocardium to recover. "It's like providing an elastic sock on a tired leg muscle," says Rohrbaugh. "It absorbs some of those fatiguing stresses, and when the myocardium recovers, the heart is able to improve its contractility and relaxation properties so that it pumps more efficiently."

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT037090

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel